Inhibitors of the biosynthesis and processing of N-linked oligosaccharides.
A number of glycoproteins have oligosaccharides linked to protein in a GlcNAc----asparagine bond. These oligosaccharides may be either of the complex, the high-mannose or the hybrid structure. Each type of oligosaccharides is initially biosynthesized via lipid-linked oligosaccharides to form a Glc3Man9GlcNAc2-pyrophosphoryl-dolichol and transfer of this oligosaccharide to protein. The oligosaccharide portion is then processed, first of all by removal of all three glucose residues to give a Man9GlcNAc2-protein. This structure may be the immediate precursor to the high-mannose structure or it may be further processed by the removal of a number of mannose residues. Initially four alpha 1,2-linked mannoses are removed to give a Man5 - GlcNAc2 -protein which is then lengthened by the addition of a GlcNAc residue. This new structure, the GlcNAc- Man5 - GlcNAc2 -protein, is the substrate for mannosidase II which removes the alpha 1,3- and alpha 1,6-linked mannoses . Then the other sugars, GlcNAc, galactose, and sialic acid, are added sequentially to give the complex types of glycoproteins. A number of inhibitors have been identified that interfere with glycoprotein biosynthesis, processing, or transport. Some of these inhibitors have been valuable tools to study the reaction pathways while others have been extremely useful for examining the role of carbohydrate in glycoprotein function. For example, tunicamycin and its analogs prevent protein glycosylation by inhibiting the first step in the lipid-linked pathway, i.e., the formation of Glc NAc-pyrophosphoryl-dolichol. These antibiotics have been widely used in a number of functional studies. Another antibiotic that inhibits the lipid-linked saccharide pathway is amphomycin, which blocks the formation of dolichyl-phosphoryl-mannose. In vitro, this antibiotic gives rise to a Man5GlcNAc2 -pyrophosphoryl-dolichol from GDP-[14C]mannose, indicating that the first five mannose residues come directly from GDP-mannose rather than from dolichyl-phosphoryl-mannose. Other antibodies that have been shown to act at the lipid-level are diumycin , tsushimycin , tridecaptin, and flavomycin. In addition to these types of compounds, a number of sugar analogs such as 2-deoxyglucose, fluoroglucose , glucosamine, etc. have been utilized in some interesting experiments. Several compounds have been shown to inhibit glycoprotein processing. One of these, the alkaloid swainsonine , inhibits mannosidase II that removes alpha-1,3 and alpha-1,6 mannose residues from the GlcNAc- Man5GlcNAc2 -peptide. Thus, in cultured cells or in enveloped viruses, swainsonine causes the formation of a hybrid structure.(ABSTRACT TRUNCATED AT 400 WORDS)
D017485:1-Deoxynojirimycin; D000117:Acetylglucosamine / Q000378:metabolism; D000470:Alkaloids / Q000494:pharmacology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001216:Asparagine; D001414:Bacitracin / Q000494:pharmacology; D001692:Biological Transport / Q000187:drug effects; D002236:Carbohydrate Conformation; D053138:Cyclohexenes; D004288:Dolichol Phosphates / Q000378:metabolism; D005944:Glucosamine / Q000031:analogs & derivatives / Q000494:pharmacology; D005947:Glucose / Q000031:analogs & derivatives / Q000378:metabolism; D006023:Glycoproteins / Q000096:biosynthesis*; D006888:Hydroxycholesterols / Q000494:pharmacology; D007212:Indolizines; D007294:Inositol / Q000031:analogs & derivatives / Q000494:pharmacology; D055666:Lipopeptides; D008148:Lovastatin / Q000031:analogs & derivatives*; D008358:Mannose / Q000031:analogs & derivatives / Q000378:metabolism; D009281:Naphthalenes / Q000494:pharmacology; D009842:Oligopeptides / Q000494:pharmacology; D009844:Oligosaccharides / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010455:Peptides / Q000494:pharmacology; D010456:Peptides, Cyclic; D010743:Phospholipids / Q000494:pharmacology; D011103:Polyisoprenyl Phosphate Monosaccharides / Q000096:biosynthesis; D011741:Pyrimidine Nucleosides; D012787:Showdomycin / Q000494:pharmacology; D013329:Structure-Activity Relationship; D017026:Swainsonine; D014415:Tunicamycin / Q000494:pharmacology; D014498:Uracil; D054836:Indolizidines
D017485:1-Deoxynojirimycin; D000117:Acetylglucosamine; D000470:Alkaloids; D000900:Anti-Bacterial Agents; D001216:Asparagine; D001414:Bacitracin; D053138:Cyclohexenes; D004288:Dolichol Phosphates; D005944:Glucosamine; D005947:Glucose; D006023:Glycoproteins; D006888:Hydroxycholesterols; D007212:Indolizines; D007294:Inositol; D055666:Lipopeptides; D008148:Lovastatin; D008358:Mannose; D009281:Naphthalenes; D009842:Oligopeptides; D009844:Oligosaccharides; D010455:Peptides; D010456:Peptides, Cyclic; D010743:Phospholipids; D011103:Polyisoprenyl Phosphate Monosaccharides; D011741:Pyrimidine Nucleosides; D012787:Showdomycin; D017026:Swainsonine; D014415:Tunicamycin; D014498:Uracil; C031299:tsushimycin; C026602:diumycin; C028306:dolichol monophosphate; C012258:mevastatin; C036388:6-bromoconduritol; C004423:amphomycin; C009329:streptovirudin; C018439:N-acetylglucosaminylpyrophosphoryldolichol; C007997:25-hydroxycholesterol; C037806:castanospermine; D054836:Indolizidines